Doccla

"Preventing tomorrow's admissions today: Virtual wards" [1]

Where it wins

• Passive, non-invasive monitoring — Ergonomic devices collect vital signs automatically during sleep and activity, removing the compliance burden of intermittent self-reporting [1].
• End-to-end operational model — Doccla’s dedicated support team handles remote onboarding, live device guidance, and engagement monitoring, freeing clinical staff to focus on care [1].
• Proven NHS scale and outcomes — Deployed across 11 European countries with 2,500+ new patients onboarded monthly in the UK&I, delivering a 34% reduction in non-elective admissions (NEL) in BNSSG ICB [1].
• Deep equity and reach — Captures 1 in 5 patients from the most deprived deciles (IMD Decile 1), ensuring virtual wards serve the populations most at risk of hospitalisation [1].

Credibility: Direct claims of patient volume, NEL reduction, and device ergonomics are sourced from the Doccla homepage, which lists specific NHS Trusts and Integrated Care Boards (ICBs) as active deployments [1].

• Platform-as-a-Service (PaaS) for Virtual Care — Doccla operates a unified platform that integrates passive monitoring hardware with clinical dashboards, enabling scalable virtual ward deployments [1].
• Task-Shifting and Capacity Liberation — The business model centres on freeing up NHS clinical capacity by automating vital sign collection and handling patient onboarding through Doccla’s support team [1].
• Outcome-Driven Value Proposition — Revenue is justified by measurable reductions in non-elective admissions (NEL) and significant cost avoidance (£58m potential savings per ICB for COPD/HF cohorts) [1].
• Modular Service Architecture — Solutions are tailored to specific NHS needs, allowing trusts to adopt specific modules (e.g., proactive care, health coaching) rather than a monolithic contract [1].

Credibility: The "end-to-end service" and "modular solutions" are explicitly stated on the homepage, alongside the financial impact on ICBs [1].

• Traditional Remote Monitoring Providers — Competitors often rely on active patient reporting and intermittent device use, leading to lower compliance [1].
• Hospital-Centric Care Models — Traditional models focus on acute care, lacking the proactive, home-based infrastructure that Doccla provides [1].
• General Telehealth Platforms — Broad telehealth solutions often lack the deep clinical integration and passive monitoring capabilities required for virtual wards [1].
• Differentiators — Doccla’s passive hardware, dedicated support team, and proven NHS outcomes (34% NEL reduction) create a significant barrier to entry [1].
• Threats — Large tech companies or established medical device manufacturers could enter the passive monitoring space, leveraging their existing distribution networks [1].

Credibility: The competitive landscape is inferred from Doccla’s unique value proposition of passive monitoring and end-to-end service [1].

• High Non-Elective Admission Rates — NHS trusts face pressure to reduce avoidable hospital admissions, which are costly and strain capacity [1].
• Patient Non-Compliance — Traditional remote monitoring devices require active patient participation, leading to poor data quality and engagement [1].
• Clinical Workforce Shortages — NHS staff are stretched thin, requiring solutions that can task-shift monitoring and onboarding to non-clinical teams [1].
• Health Inequities — Vulnerable populations, including those in deprived areas (IMD Decile 1), are at higher risk of hospitalisation and need accessible care [1].
• Fragmented Care Pathways — Lack of integrated tools for proactive care and continuous monitoring leads to reactive, rather than preventive, treatment [1].

Credibility: These pains are addressed by Doccla’s value proposition of passive monitoring, dedicated support, and proven NEL reduction [1].

Doccla’s focus on passive monitoring and dedicated support directly addresses the NHS’s critical need to reduce non-elective admissions and manage workforce shortages. The proven outcomes in BNSSG ICB provide a strong reference model for scaling across other ICBs. The main risk is dependency on NHS procurement cycles and budget constraints. Expansion into European markets and additional chronic disease cohorts (beyond COPD/HF) represents a significant growth opportunity. The next key signal to watch is the adoption rate of Doccla’s platform by new ICBs and the potential for outcome-based pricing models to become standard.

Doccla should accelerate the development of predictive analytics capabilities to further enhance proactive care and reduce admissions. Expanding the range of supported chronic conditions beyond COPD and HF would unlock new market segments. Investing in patient-facing mobile app features could further improve engagement and compliance. Forming strategic partnerships with health insurance providers in Europe could diversify revenue streams and reduce reliance on NHS funding.